Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, Republic of Korea; Department of Pediatrics, Kyung Hee University College of Medicine, Seoul, Republic of Korea.
J Arthroplasty. 2024 May;39(5):1374-1383.e3. doi: 10.1016/j.arth.2023.11.012. Epub 2023 Nov 14.
The aim of this study was to investigate the safety of early surgery in hip fracture patients who took clopidogrel and/or aspirin.
A systematic search was conducted using databases, including PubMed/MEDLINE, Embase, Cochrane Library, and Web of Science, for studies relating to early arthroplasty or internal fixation for femoral neck fractures, intertrochanteric fractures, and subtrochanteric fractures in patients taking clopidogrel and/or aspirin. A total of 20 observational studies involving 3,077 patients were included in this meta-analysis, and analyzed in groups of early surgery versus delayed surgery, and clopidogrel and/or aspirin versus nonantiplatelet agents.
Patients in the clopidogrel and/or aspirin group who underwent early surgery had significantly more intraoperative blood loss than those in the non-antiplatelet group (mean difference = 17.96, 95% confidence interval [CI] [4.37, 31.55], P = .01), and patients in the clopidogrel and/or aspirin group had a lower overall incidence of complications after early surgery than those in the delayed surgery group (odds ratio = 0.26, 95% CI [0.14, 0.29], P < .001) and a shorter length of hospital stay (odds ratio = 0.26, 95% CI [0.14, 0.29], P < .001). There was no significant difference in postoperative mortality and other related indicators.
Early surgery in hip fracture patients taking clopidogrel and/or aspirin appears to be safe based on the available evidence and needs to be clarified by higher quality studies. However, the increased risk of cardiovascular events associated with discontinuation of clopidogrel or clopidogrel combined with aspirin dual antiplatelet therapy requires attention in the perioperative period.
本研究旨在探讨服用氯吡格雷和/或阿司匹林的髋部骨折患者行早期手术的安全性。
通过检索 PubMed/MEDLINE、Embase、Cochrane 图书馆和 Web of Science 等数据库,对涉及服用氯吡格雷和/或阿司匹林的患者行早期人工关节置换术或股骨颈骨折、转子间骨折和转子下骨折内固定术的研究进行了系统评价。本 meta 分析共纳入 20 项观察性研究,共计 3077 例患者,分为早期手术组与延迟手术组、氯吡格雷和/或阿司匹林组与非抗血小板组进行分析。
氯吡格雷和/或阿司匹林组行早期手术的患者术中出血量显著多于非抗血小板组(均数差值=17.96,95%置信区间 [CI] [4.37, 31.55],P=.01),且氯吡格雷和/或阿司匹林组行早期手术后并发症总发生率低于延迟手术组(比值比=0.26,95%CI [0.14, 0.29],P<.001),住院时间更短(比值比=0.26,95%CI [0.14, 0.29],P<.001)。术后死亡率及其他相关指标两组间差异无统计学意义。
现有证据表明,服用氯吡格雷和/或阿司匹林的髋部骨折患者行早期手术似乎是安全的,但需要更高质量的研究加以证实。然而,停用氯吡格雷或氯吡格雷联合阿司匹林双联抗血小板治疗可能会增加心血管事件风险,这在围手术期需要引起重视。